Tonix Pharma Relocates Executive Offices
Ticker: TNXP · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1430306
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
Tonix Pharma moved its HQ to Chatham, NJ.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on February 7, 2025, reporting on events that occurred on the same date. The filing indicates a change in the company's principal executive offices to 26 Main Street, Suite 101, Chatham, New Jersey 07928. The company, previously known as Tamandare Explorations Inc. until March 20, 2008, is incorporated in Nevada and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing signals a physical operational change for Tonix Pharmaceuticals, potentially impacting logistics, employee location, or strategic positioning.
Risk Assessment
Risk Level: low — The filing primarily concerns a change of address for executive offices, which is a routine administrative update with low immediate risk.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- Tamandare Explorations Inc. (company) — Former company name
- 26 Main Street, Suite 101, Chatham, New Jersey 07928 (location) — New principal executive offices
- 20080320 (date) — Date of name change
- 20250207 (date) — Report date
FAQ
What is the new address for Tonix Pharmaceuticals Holding Corp.'s principal executive offices?
The new address for Tonix Pharmaceuticals Holding Corp.'s principal executive offices is 26 Main Street, Suite 101, Chatham, New Jersey 07928.
When was the company formerly known as Tamandare Explorations Inc.?
The company was formerly known as Tamandare Explorations Inc. until March 20, 2008.
In which state is Tonix Pharmaceuticals Holding Corp. incorporated?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.
What is the SIC code for Tonix Pharmaceuticals Holding Corp.?
The Standard Industrial Classification (SIC) code for Tonix Pharmaceuticals Holding Corp. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 8-K report?
The filing date of this 8-K report is February 7, 2025.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-02-07 08:52:48
Filing Documents
- tnxp-8k_020725.htm (8-K) — 26KB
- ex99-01.htm (EX-99.01) — 32KB
- 0001999371-25-001293.txt ( ) — 235KB
- tnxp-20250207.xsd (EX-101.SCH) — 3KB
- tnxp-20250207_lab.xml (EX-101.LAB) — 33KB
- tnxp-20250207_pre.xml (EX-101.PRE) — 24KB
- tnxp-8k_020725_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On February 7, 2025, the Company repeated recently announced certain year-end 2024 financial information. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 104 Press Release of the Company, February 7, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: February 7, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer